Loading…
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $10M | $-184M | $-244M | $-164M | -87.0% | -92.8% | 99.6% |
| 2024 | $135M | $-154M | $-122M | $-150M | -25.1% | 47.9% | -16.8% |
| 2023 | $91M | $-190M | $-147M | $-137M | -26.2% | 69.5% | 25.7% |
| 2022 | $54M | $-131M | $-117M | $-109M | -18.8% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 53.90 | 91.37 | 135.16 | 9.68 |
| Operating Revenue | - | 53.90 | 91.37 | 135.16 | 9.68 |
| Operating Expense | - | 185.46 | 282.41 | 289.72 | 194.24 |
| Research And Development | - | 135.56 | 220.57 | 222.52 | 134.85 |
| Selling General And Administration | - | 49.90 | 61.84 | 67.20 | 59.39 |
| Total Expenses | - | 185.46 | 282.41 | 289.72 | 194.24 |
| Operating Income | - | -131.56 | -191.04 | -154.56 | -184.56 |
| Total Operating Income As Reported | - | -131.56 | -191.04 | -154.56 | -214.64 |
| EBITDA | - | -130.81 | -190.11 | -153.67 | -183.66 |
| Normalized EBITDA | - | -130.42 | -189.65 | -153.48 | -153.26 |
| EBIT | - | -131.56 | -191.04 | -154.56 | -184.56 |
| Interest Income | - | 6.35 | 31.01 | 25.82 | 14.14 |
| Net Interest Income | - | 6.35 | 31.01 | 25.82 | 14.14 |
| Other Non Operating Income Expenses | -0.10 | -0.40 | -0.46 | - | - |
| Other Income Expense | - | -0.40 | -0.46 | -0.18 | -30.41 |
| Interest Income Non Operating | - | 6.35 | 31.01 | 25.82 | 14.14 |
| Net Non Operating Interest Income Expense | - | 6.35 | 31.01 | 25.82 | 14.14 |
| Pretax Income | - | -125.60 | -160.48 | -128.93 | -200.83 |
| Tax Provision | - | -8.66 | -13.45 | -6.62 | 43.26 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | -0.03 | -0.04 | -0.01 | -3.80 |
| Net Income Continuous Operations | - | -116.95 | -147.03 | -122.31 | -244.09 |
| Net Income From Continuing And Discontinued Operation | - | -116.95 | -147.03 | -122.31 | -244.09 |
| Net Income From Continuing Operation Net Minority Interest | - | -116.95 | -147.03 | -122.31 | -244.09 |
| Net Income | - | -116.95 | -147.03 | -122.31 | -244.09 |
| Net Income Common Stockholders | - | -116.95 | -147.03 | -122.31 | -244.09 |
| Net Income Including Noncontrolling Interests | - | -116.95 | -147.03 | -122.31 | -244.09 |
| Normalized Income | - | -116.58 | -146.61 | -122.13 | -217.48 |
| Diluted NI Availto Com Stockholders | - | -116.95 | -147.03 | -122.31 | -244.09 |
| Basic Average Shares | - | 47.37 | 53.22 | 53.77 | 53.83 |
| Diluted Average Shares | - | 47.37 | 53.22 | 53.77 | 53.83 |
| Reconciled Depreciation | - | 0.74 | 0.93 | 0.89 | 0.90 |
| Total Unusual Items | - | -0.40 | -0.46 | -0.18 | -30.41 |
| Total Unusual Items Excluding Goodwill | - | -0.40 | -0.46 | -0.18 | -30.41 |
| Special Income Charges | 0 | - | 0 | 0 | -30.08 |
| Restructuring And Mergern Acquisition | 0 | - | 0 | 0 | 30.08 |
| Gain On Sale Of Security | - | -0.40 | -0.46 | -0.18 | -0.33 |
| General And Administrative Expense | - | 49.90 | 61.84 | 67.20 | 59.39 |
| Other Gand A | - | 49.90 | 61.84 | 67.20 | 59.39 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Prothena Corporation plcthis co. | PRTA | $484M | -1.98 | 1.73 | -87.0% | -1.01 |
| Pacific Biosciences of California, Inc. | PACB | $506M | -0.93 | 94.65 | -10214.5% | -7.50 |
| Arvinas, Inc. | ARVN | $499M | -6.18 | 1.15 | -18.6% | -3.23 |
| AngioDynamics, Inc. | ANGO | $497M | -14.62 | 2.72 | -18.6% | 256.27 |
| Standard BioTools Inc. | LAB | $496M |
| - |
| - |
| - |
| - |
| - |
| - |
| -6.62 |
| 1.17 |
| -17.7% |
| -4.73 |
| Evolent Health, Inc. | EVH | $493M | -0.92 | 1.19 | -128.7% | -3.68 |
| The Oncology Institute, Inc. | TOI | $474M | -7.82 | -30.15 | 385.5% | -12.80 |
| CTEV | CTEV | $470M | - | - | 163.5% | 10.85 |
| OrthoPediatrics Corp. | KIDS | $465M | -11.73 | 1.34 | -11.4% | -69.20 |
| Peer Median | - | -6.62 | 1.19 | -18.1% | -4.21 | |